PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI
نویسندگان
چکیده
منابع مشابه
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
PURPOSE The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, proc...
متن کاملABVD or BEACOPP for Advanced Hodgkin Lymphoma.
The development of multiagent chemotherapy dramatically changed the prognosis of patients with advanced-stage Hodgkin lymphoma (HL). Although almost all of these patients died when treated with radiotherapy or single-agent chemotherapy, the fourdrug regimen MOPP (mustargen, oncovin, procarbazine, and prednisone) led to remission rates of more than 50% and an overall survival (OS) rate of more t...
متن کاملABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
BACKGROUND Between January 1996 and April 2000, 355 patients with advanced Hodgkin's disease (HD) (stage II bulky disease, III and IV) were enrolled in a prospective, multicentre, randomised trial aimed at comparing the efficacy of two new promising regimens: Stanford V and MEC hybrid. ABVD was chosen as the control arm. Radiotherapy was planned at the end of induction therapy on residual masse...
متن کاملSafety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
The efficacy of rituximab alone in the treatment of B-cell non-Hodgkin lymphoma (NHL) has been well estab-lished since 1999. Furthermore, the addition of rituximab to conventional chemotherapy improved survival outcome. Lenalidomide (Celgene Corp., Summit, NJ, USA) a potent immunomodulatory agent, has shown efficacy in patients with relapsed or refractory indolent NHL. The combination of these ...
متن کاملNeutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: HemaSphere
سال: 2019
ISSN: 2572-9241
DOI: 10.1097/01.hs9.0000563228.79887.e0